Last updated on April 2017

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors


Brief description of study

This is an open-label, two-part, multiple study to evaluate the safety and tolerability of DS-8201a in patients with advanced solid malignant tumors.

Detailed Study Description

This study is one single group of participants in two periods. It is therefore not randomized. The dosage strength will change during the study but all participants will receive the same study drug DS-8201a. So the study is not a true 2 arm study, it is a 2 part study.

Clinical Study Identifier: NCT02564900

Contact Investigators or Research Sites near you

Start Over

Yoshihiko Fujisaki, DL

National Cancer Center Hospital
Tokyo-to, Japan
  Connect »

Yoshihiko Fujisaki, DL

The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Tokyo-to, Japan
  Connect »